# A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

> **NCT00701415** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 31 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Agalsidase beta
- **BIOLOGICAL:** Agalsidase beta

## Key facts

- **NCT ID:** NCT00701415
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701415, "A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00701415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*